MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Pharmaceutical Biotechnology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1389201015666140519104743PMID 24846067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MiR‐503 Regulates Osteoclastogenesis via Targeting RANK

  2014cited by this paper
• Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma

  2014cited by this paper
• In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

  2014cited by this paper
• In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells

  2014cited by this paper
• MicroRNAs in human cancer.

  2013cited by this paper
• Adult-specific functions of animal microRNAs

  2013cited by this paper
• CLIP-based prediction of mammalian microRNA binding sites

  2013cited by this paper
• Immunologic microenvironment and personalized treatment in multiple myeloma

  2013cited by this paper
• Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

  2013cited by this paper
• miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.

  2013cited by this paper
• MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines

  2013cited by this paper
• Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

  2013cited by this paper
• The Role of Denosumab for Prevention of Skeletal-Related Complications in Multiple Myeloma

  2013cited by this paper
• In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

  2013cited by this paper
• International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

  2013cited by this paper
• Emerging pathways as individualized therapeutic target of multiple myeloma

  2013cited by this paper
• miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

  2013cited by this paper
• Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium.

  2012cited by this paper
• Molecular targets for the treatment of multiple myeloma.

  2012cited by this paper
• miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

  2012cited by this paper
• DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

  2012cited by this paper
• DNA methylation of microRNA genes in multiple myeloma.

  2012cited by this paper
• Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

  2012cited by this paper
• MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma.

  2012cited by this paper
• MicroRNA profiling: approaches and considerations

  2012cited by this paper
• Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

  2012cited by this paper
• MicroRNAs as therapeutic targets and their potential applications in cancer therapy

  2012cited by this paper
• Interferon‐β‐induced miR‐155 inhibits osteoclast differentiation by targeting SOCS1 and MITF

  2012cited by this paper
• The art of microRNA research.

  2011cited by this paper
• miREE: miRNA recognition elements ensemble

  2011cited by this paper
• Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

  2011cited by this paper
• Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants.

  2011cited by this paper
• A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

  2011cited by this paper
• Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

  2011cited by this paper
• Experimental strategies for microRNA target identification

  2011cited by this paper
• miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.

  2011cited by this paper
• Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation

  2011cited by this paper
• Current progress of siRNA/shRNA therapeutics in clinical trials

  2011cited by this paper
• Desperately seeking microRNA targets

  2010cited by this paper
• Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b

  2010cited by this paper
• Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo

  2010cited by this paper
• High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

  2010cited by this paper
• Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling

  2010cited by this paper
• Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

  2010cited by this paper
• Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

  2010cited by this paper
• Expression profiling of microRNAs by deep sequencing

  2009cited by this paper
• Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma

  2009cited by this paper
• Regression of murine lung tumors by the let-7 microRNA

  2009cited by this paper
• Computational Challenges in miRNA Target Predictions: To Be or Not to Be a True Target?

  2009cited by this paper
• A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function

  2009cited by this paper
• A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

  2009cited by this paper
• Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

  2009cited by this paper
• Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.

  2009cited by this paper
• MicroRNAs: Target Recognition and Regulatory Functions

  2009cited by this paper
• MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

  2009cited by this paper
• Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.

  2009cited by this paper
• Clustered microRNAs' coordination in regulating protein-protein interaction network

  2009cited by this paper
• Direct multiplexed measurement of gene expression with color-coded probe pairs

  2008cited by this paper
• MicroRNAs 221 and 222 bypass quiescence and compromise cell survival.

  2008cited by this paper
• MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

  2008cited by this paper
• Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot

  2007cited by this paper
• microRNAs join the p53 network — another piece in the tumour-suppression puzzle

  2007cited by this paper
• Principles and Limitations of Computational MicroRNA Gene and Target Finding

  2007cited by this paper
• Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.

  2007cited by this paper
• Impaired microRNA processing enhances cellular transformation and tumorigenesis

  2007cited by this paper
• Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.

  2007cited by this paper
• Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation

  2007cited by this paper
• Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?

  2006cited by this paper
• Spatio-temporal accumulation of microRNAs is highly coordinated in developing plant tissues.

  2006cited by this paper
• A guide through present computational approaches for the identification of mammalian microRNA targets

  2006cited by this paper
• microRNA target predictions in animals

  2006cited by this paper
• Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis

  2005cited by this paper
• MicroRNA Expression in Zebrafish Embryonic Development

  2005cited by this paper
• Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells

  2005cited by this paper
• Real-time quantification of microRNAs by stem–loop RT–PCR

  2005cited by this paper
• Silencing of polo‐like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer

  2005cited by this paper
• Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

  2005cited by this paper
• The functions of animal microRNAs

  2004cited by this paper
• Identification of mammalian microRNA host genes and transcription units.

  2004cited by this paper
• Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

  2002cited by this paper
• The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.

  2002cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002cited by this paper

• Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation

  2024cites this paper
• Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer

  2023cites this paper
• A study to identify novel biomarkers associated with multiple myeloma

  2023cites this paper
• MicroRNA-142-5p promotes the proliferation and metastasis of nasopharyngeal carcinoma

  2023cites this paper
• Delivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies

  2022cites this paper
• MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and Perspectives

  2022cites this paper
• Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma

  2022cites this paper
• miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

  2022cites this paper
• MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease

  2021cites this paper
• miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

  2020cites this paper
• Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats

  2020cites this paper
• DNA complexes as an efficient gene anticancer drug delivery therapy

  2019cites this paper
• microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF

  2019cites this paper
• Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

  2019cites this paper
• Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma

  2019cites this paper
• Aberrant Epigenomic Regulatory Networks in Multiple Myeloma and Strategies for Their Targeted Reversal

  2019cites this paper
• The potential role of miRNAs in multiple myeloma therapy

  2018cites this paper
• The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma

  2018cites this paper
• Multiple Myeloma: Personalised Medicine Based on Pathogenesis

  2018cites this paper
• Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment

  2017cites this paper
• Precision Oncology: Present Status and Perspectives

  2017cites this paper
• Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

  2017cites this paper
• Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

  2017cites this paper
• Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation

  2017cites this paper
• Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma

  2017cites this paper
• Molecular Targets and Strategies in Cancer Prevention

  2016cites this paper
• Functional Analysis of microRNA in Multiple Myeloma.

  2016cites this paper
• MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment

  2016cites this paper
• Therapeutic nucleic acids: current clinical status

  2016cites this paper
• Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors

  2016cites this paper
• Mir-221/222 are promising targets for innovative anticancer therapy

  2016cites this paper
• Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates

  2016cites this paper
• Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

  2016cites this paper
• Experimental treatment of multiple myeloma in the era of precision medicine

  2016cites this paper
• Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules

  2016cites this paper
• Targeting MicroRNAs: Molecular Basis of Cancer Prevention

  2016cites this paper
• Gene interference strategies as a new tool for the treatment of prostate cancer

  2015cites this paper
• Emerging role of microRNAs in breast cancer radiotherapy

  2015cites this paper
• Multiple myeloma-related bone disease: state-of-art and next future treatments

  2015cites this paper
• Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

  2015cites this paper
• MicroRNAs in multiple myeloma and related bone disease.

  2015cites this paper
• Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a∼125b cluster function by seed-targeting inhibitors in multiple myeloma cells

  2015cites this paper
• Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

  2015cites this paper
• Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

  2015cites this paper
• New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics

  2015cites this paper
• Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma

  2015cites this paper
• Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine

  2015cites this paper
• miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

  2015cites this paper
• MicroRNAs in Inflammatory Bowel Diseases: Paradoxes and Possibilities

  2015cites this paper
• Mir-34: A New Weapon Against Cancer?

  2014cites this paper